Suciu, N., Crețoiu, D., Ciuvică, Adriana Irina, Suciu, Ioan Dumitru, Georgescu, T. A., and Micu, Romeo
The ideal screening test for cervical cancer is the one that has the ability to correctly and effectively identify all patients with premalignant changes, while at the same time exclude those without changes. Unfortunately, no test is perfect. Cervicovaginal cytology is the traditional screening method, independently described by Aurel Babeș and George Papanicolaou in 1927 and 1928, respectively. Data from the scientific literature report a relatively low sensitivity for conventional cytology, ranging from 20% to 50%, and a specificity in the identification of HSIL lesions that can reach up to 90%, based on the experience of the examiner. Given the mechanism of cervical carcinogenesis, the detection of human papillomavirus (HPV) infection is currently one of the main screening alternatives, especially in the context of the dramatic cost reductions which occurred in the recent years. HPV testing may have a sensitivity of up to 17% higher compared to classical cytology, but the latter is known for a slightly increased specificity compared to HPV testing. Although HPV testing is more effective in identifying highgrade lesions, it generates more indications for colposcopy. However, a negative HPV result is more encouraging than a negative cytological result, because the cytological examination is more likely to be false negative, which would lead to delays in the application of appropriate treatment. Regardless of age group stratification, cytological and HPV cotesting have a much higher sensitivity (>92%) in the identification of premalignant lesions compared to isolated testing. [ABSTRACT FROM AUTHOR]